The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Targeting the androgen receptor pathway in prostate cancer
Open accessAbstract
Summary of recent advances When prostate cancers progress following androgen depletion therapy, there are currently few treatment options with only one, docetaxel, that has been shown to prolong life. Recent work has shown that castration resistant prostate cancers (CRPC) continue to depend on androgen receptor (AR) signaling which is reactivated despite low serum androgen levels. Currently available AR targeted therapy, including GnRH agonists and antiandrogens, cannot completely shut down AR signaling. Several mechanisms that enhance AR signaling in an androgen depleted environment have been elucidated. These include AR mutations that allow activation by low androgen levels or by other endogenous steroids, AR overexpression, increased local intracrine synthesis of androgens, and upregulation of tyrosine kinase pathways. This has led to the development of a number of novel agents targeting AR signaling pathway, including more effective antiandrogens, inhibitors of CYP17, an enzyme required for androgen synthesis, inhibitors of 5α-reductase, inhibitors of HSP90 which protects AR from degradation, inhibitors of histone deacetylases which is required for optimal AR mediated transcription, as well as inhibitors of tyrosine kinase inhibitors. Many of these strategies are currently being tested in clinical trials in CRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citationHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationCraft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Self-citationRosenfeld, M. G., Lunyak, V. V., & Glass, C. K. (2006) · Genes & Development · doi:10.1101/gad.1424806 · Cited by 952
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.158 · Cited by 758
Yeh, S., Tsai, M.-Y., Xu, Q., Mu, X.-M., Lardy, H., Huang, K.-E., Lin, H., Yeh, S.-D., Altuwaijri, S., Zhou, X., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212474399 · Cited by 668
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationBubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 594
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Self-citationMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Small, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
Self-citationAndrogen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601879 · Cited by 382
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
Kevin Kelly, W., & Scher, H. I. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36163-3 · Cited by 349
Self-citationMellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 1×
“In experimental systems, forced overexpression of HER2 results in increased AR activity and stability while pharmacologic inhibition or knockdown of the protein results in growth suppression [29].”
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
Pharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Self-citationBicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., & Schwartz, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2928 · Cited by 227
Self-citationThe use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D. (2004) · The Prostate · doi:10.1002/pros.20065 · Cited by 181
Fosså, S. D., Slee, P. H. T., Brausi, M., Horenblas, S., Hall, R. R., Hetherington, J. W., Aaronson, N., de Prijck, L., & Collette, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.62 · Cited by 179
Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E. T., & Namiki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0130 · Cited by 175
Hsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 146
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer
Thomas, L. N., Douglas, R. C., Lazier, C. B., Too, C. K. L., Rittmaster, R. S., & Tindall, D. J. (2007) · European Urology · doi:10.1016/j.eururo.2007.10.052 · Cited by 131
Kraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 116
Self-citationMarrocco, D. L., Tilley, W. D., Bianco‐Miotto, T., Evdokiou, A., Scher, H. I., Rifkind, R. A., Marks, P. A., Richon, V. M., & Butler, L. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0144 · Cited by 109
Self-citationPharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers
Xu, Y. J., Dalrymple, S. L., Becker, R. E., Denmeade, S. R., & Isaacs, J. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0184 · Cited by 105
Chen, L., Meng, S., Wang, H., Bali, P., Bai, W., Li, B., Atadja, P. W., Bhalla, K. N., & Wu, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0287 · Cited by 99
Migliaccio, A., Varricchio, L., de Falco, A., Castoria, G., Arra, C., Yamaguchi, H., Ciociola, A., Lombardi, M., Stasio, R. D., Barbieri, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210487 · Cited by 98
Androgen receptor mutations and androgen insensitivity
McPhaul, M. J. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00369-6 · Cited by 94
Ryan, C. J., Halabi, S., Ou, S., Vogelzang, N. J., Kantoff, P. W., Small, E. J., & for the Cancer and Leukemia Group B (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2344 · Cited by 93
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1637 · Cited by 87
Gross, M. E., Higano, C. S., Pantuck, A. J., Castellanos, O. O., Green, E., NGUYEN, K. N., & Agus, D. B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-142 · Cited by 84
Yuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R. A., Bubley, G. J., Lu, M. L., & Balk, S. P. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051047 · Cited by 75
Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0085 · Cited by 66
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Fleming, M. T., Morris, M. J., Heller, G., & Scher, H. I. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0664 · Cited by 61
Self-citationKorkmaz, C. G., Frønsdal, K. B., Zhang, Y., Lorenzo, P. I., & Saatcioglu, F. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1820377 · Cited by 47
Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
Slovin, S. F. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0435 · Cited by 28
Curigliano, G., de Braud, F., Sandri, M. T., Renne, G., Zorzino, L., Scardino, E., Rocco, B. M. C., Spitaleri, G., Pas, T. M. D., Noberasco, C., et al. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328136c162 · Cited by 12
Cited by
EDC-2: the endocrine society's second scientific statement on endocrine-disrupting chemicals
Gore, A. C., Chappell, V. A., Fenton, S. E., Flaws, J. A., Nadal, A., Prins, G. S., Toppari, J., & Zoeller, R. T. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1010 · Cited by 2,407
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Metadata
- Authors
- Chen, Y., Sawyers, C. L., & Scher, H. I.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 8
- Issue
- 4
- Pages
- 440-448
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2141255350
- Cited by
- 389
- References
- 65
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.